Built to find clinically meaningful signals—and move them toward use.

Existential Intelligence brings together cancer biology, clinical research, biomedical informatics, artificial intelligence, software engineering, and cybersecurity to address difficult problems in oncology.

We believe the most valuable cancer insights often emerge when specialized clinical knowledge is connected with imaging, pathology, biomarkers, and patient outcomes.

Clinical question

Clinical and translational oncologyBiomedical informaticsComputational biology and AISecure software and product engineering

Integrated evidence across imaging, pathology, biomarkers, outcomes, and secure product systems.

Founding team

Clinical science, computational intelligence, and secure product development.

Our founders bring together expertise in pancreatic cancer, radiology and pathology-informed research, biomedical informatics, computational biology, artificial intelligence, software engineering, and cybersecurity.

Dr. Kirk Gasper, Ph.D.

CEO, informatics lead, co-founder

Dr. Kirk Gasper is a biomedical informatics scientist focused on discovering cancer biology and improving clinically meaningful outcomes for cancer patients. He earned his Ph.D. from the University of Nebraska at Omaha under the guidance of Dr. Dario Ghersi and Dr. Matteo Ligorio.

His work supports efforts to understand the spatial biology of pancreatic ductal adenocarcinoma, including the role of macrovascular infiltration in cancer progression. At Existential Intelligence, he leads company strategy, biomedical informatics, and the translation of scientific opportunities into focused development programs.

Dr. Matteo Ligorio, M.D.

Surgical lead, macrovascular invasion lead, co-founder

Dr. Matteo Ligorio is a physician-scientist with expertise in pancreatic cancer biology, clinical research, and translational oncology. He earned his M.D. from the University of Genoa and a Ph.D. in molecular epidemiology and biostatistics from Harvard Medical School, followed by appointments at Harvard, Massachusetts General Hospital, and UT Southwestern.

His research has advanced the understanding of pancreatic tumor behavior, patient-survival predictors, and therapeutic delivery approaches, with work published in leading scientific journals. At Existential Intelligence, he guides clinical strategy, macrovascular invasion research, and the connection between scientific findings and patient-relevant applications.

Dr. Dario Ghersi, M.D., Ph.D.

Computational biology and AI lead, co-founder

Dr. Dario Ghersi is a biomedical informatics and computational biology expert with training in medicine, structural bioinformatics, cancer genomics, and machine intelligence. He earned his M.D. from the University of Genoa and his Ph.D. in Computational Biology from Mount Sinai School of Medicine, followed by postdoctoral work at Princeton University involving large-scale genome-sequencing data.

His research spans cancer genomics, immunoinformatics, structural bioinformatics, and AI-driven biomedical analysis. At Existential Intelligence, he leads computational strategy, model development, and the integration of biological knowledge with machine-learning methods.

Dr. Matt Hale, Ph.D.

Enterprise software architect, cybersecurity lead, co-founder

Dr. Matt Hale is an Associate Professor of Cybersecurity at the University of Nebraska at Omaha, Director of the Nebraska University Center for Cybersecurity, and founder of MATRIX, an AI-enabled cybersecurity workforce and operations initiative.

His research sits at the intersection of cybersecurity, software engineering, and human-centered computing. He earned his Ph.D. from the University of Tulsa, where he worked with the Air Force Office of Scientific Research on formal certification tools for information assurance in cloud-based systems. At Existential Intelligence, he leads secure software architecture, technical product development, and data-protection strategy.

Contact the team

Start a conversation with Existential Intelligence.

Contact us to discuss scientific collaboration, partnership opportunities, investment, clinical development, data validation, or another area of mutual interest.